High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• High-dose cyclophosphamide demonstrates efficacy in managing immune-mediated conditions.
• Severe refractory multiple sclerosis presents significant challenges in treatment and patient management.

Purpose of the Study:

• To evaluate the therapeutic effects of high-dose cyclophosphamide in patients with severe, treatment-resistant multiple sclerosis.
• To assess changes in clinical status, disability progression, and quality of life following high-dose cyclophosphamide administration.

Main Methods:

• A cohort of patients with multiple sclerosis (Expanded Disability Status Scale [EDSS] ≥ 3.5) refractory to multiple therapies received high-dose cyclophosphamide (200 mg/kg over 4 days).
• Clinical assessments included serial EDSS scoring, neuroimaging (MRI), and quality-of-life evaluations over a 2-year follow-up period.

Main Results:

• No patients experienced an EDSS increase >1.0; five patients showed an EDSS decrease of ≥1.0.
• Resolution of contrast-enhancing lesions was observed in two patients; minimal new lesion activity occurred in one patient.
• Significant improvements were reported across all quality-of-life parameters, alongside functional gains in gait, bladder control, and vision.

Conclusions:

• High-dose cyclophosphamide offers a potential treatment avenue for severe, refractory multiple sclerosis, leading to disease stabilization.
• This therapeutic approach can improve patient functionality and quality of life with minimal associated morbidity.
• Further research is warranted to identify optimal patient candidates for high-dose cyclophosphamide therapy.